New York, USA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Schizophrenia Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Otsuka, Boehringer Ingelheim, Merck, Sunivion, PsychoGenics, Neurocrine Biosciences, Takeda, Lyndra, Cerevel
The schizophrenia market is expected to grow significantly owing to an increase in the patient pool due to changes in lifestyle, an increase in the incidence of various addictions, the expected entry of emerging products with a deeper penetration in the schizophrenia market, etc.
DelveInsight’s Schizophrenia Market Insights report includes a comprehensive understanding of current treatment practices, schizophrenia emerging drugs, market share of individual therapies, and current and forecasted schizophrenia market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Schizophrenia Market Report
- As per DelveInsight’s analysis, the schizophrenia market size was found to be USD 8.6 billion in 2021 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
- As per DelveInsight estimates, in the year 2021, the total prevalent cases of Schizophrenia were ~6.2 million cases in the 7MM. In the 7MM, the highest number of prevalent cases of schizophrenia were observed in the US.
- Leading schizophrenia companies such as Otsuka Pharmaceutical Development & Commercialization, Inc., H. Lundbeck A/S, Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Merck, SyneuRx International (Taiwan) Corp, Reviva Pharmaceuticals, Sunivion, PsychoGenics, Neurocrine Biosciences, Takeda, Minerva Neurosciences, BioXcel Therapeutics Inc, Teva Branded Pharmaceutical Products R&D, Inc., Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others are developing novel schizophrenia drugs that can be available in the schizophrenia market in the coming years.
- Some of the key therapies for schizophrenia treatment include Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.
Discover which therapies are expected to grab the major schizophrenia market share @ Schizophrenia Market Report
Schizophrenia Overview
Schizophrenia is a serious mental disorder that significantly impairs a person’s cognitive functions, emotional regulation, decision-making abilities, and interpersonal relationships. Its origins are multifaceted, arising from a complex interplay of genetic and environmental factors. Individuals with a family history of psychosis are at a higher risk of developing schizophrenia. Symptoms of schizophrenia can vary from person to person and typically fall into three primary categories: psychotic, negative, and cognitive. Negative symptoms encompass a lack of motivation, diminished interest in daily activities, social withdrawal, emotional expression difficulties, and impaired overall functioning. Diagnosis of schizophrenia requires the exclusion of other mental health conditions and confirmation that the symptoms are not a result of substance use, medication, or a medical ailment. Diagnosing schizophrenia involves several diagnostic procedures, such as a physical examination, blood tests, and various screenings like CT scans, MRIs, as well as psychiatric evaluations utilizing assessment scales like PANSS, CGI, SANS, and more.
Schizophrenia Epidemiology Segmentation
The schizophrenia epidemiology section provides insights into the historical and current schizophrenia patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The schizophrenia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Schizophrenia Prevalent Cases
- Total Schizophrenia Diagnosed Cases
- Schizophrenia Gender-specific Cases
- Schizophrenia Severity-specific Cases
- Schizophrenia Age-specific Treated Cases
- Schizophrenia Treated Cases
Download the report to understand which factors are driving schizophrenia epidemiology trends @ Schizophrenia Epidemiological Insights
Schizophrenia Treatment Market
While there is no cure for schizophrenia, the primary objectives of treatment revolve around alleviating symptoms and preventing relapses. Schizophrenia necessitates ongoing treatment, even after symptom remission. A combination of medications and psychosocial therapy is typically employed to effectively manage the condition. In severe cases, hospitalization may be required. The pharmacological approach plays a pivotal role in treating schizophrenia, offering a range of mono and combination therapies. Antipsychotic medications are the foremost choice among psychotropic agents for schizophrenia treatment. In specific patient cohorts, treatment strategies may involve a combination of neuroleptics and antiepileptics.
Second-generation antipsychotic (SGA) medications are generally preferred due to their lower risk of severe side effects compared to first-generation antipsychotics (FGAs). FGAs carry a higher likelihood of causing significant neurological side effects, including the potential development of a potentially reversible movement disorder known as tardive dyskinesia.
Treatment options for schizophrenia encompass a range of approaches, including medication (antipsychotics), psychological counseling, social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT). While existing antipsychotic medications primarily focus on alleviating positive symptoms by targeting dopamine modulation, they often leave patients with persistent negative and cognitive symptoms. Ongoing research, coupled with a deeper understanding of the causes and mechanisms of schizophrenia, is paving the way for the creation of innovative therapies to enhance schizophrenia management and fill these existing gaps.
Learn more about the FDA-approved drugs for schizophrenia @ Drugs for Schizophrenia Treatment
Key Schizophrenia Therapies and Companies
- Brexpiprazole: Otsuka Pharmaceutical Development & Commercialization, Inc./H. Lundbeck A/S
- ICLEPERTIN (BI-425809): Boehringer Ingelheim
- KarXT (Xanomeline-Trospium): Karuna Therapeutics
- NUPLAZID (pimavanserin): Acadia Pharmaceuticals
- MK-5720: Merck
- NaBen: SyneuRx International (Taiwan) Corp
- Brilaroxazine (RP-5063): Reviva Pharmaceuticals
- ULOTARONT (SEP-363856): Sunivion/PsychoGenics/Otsuka Pharmaceuticals
- LUVADAXISTAT (NBI 1165844/TAK 831): Neurocrine Biosciences/Takeda
- Roluperidone (MIN-101): Minerva Neurosciences
- BXCL501 80: BioXcel Therapeutics Inc
- TV-44749: Teva Branded Pharmaceutical Products R&D, Inc.
- Evenamide (NW-3509/NW-3509A): Newron Pharmaceuticals
- LYN-005 (risperidone, weekly): Lyndra Therapeutics
- OKEDI (risperidone ISM): Pharmaceuticals Laboratories
- Emraclidine (CVL-231): Cerevel Therapeutics
To know more about schizophrenia clinical trials, visit @ Schizophrenia Treatment Drugs
The dynamics of schizophrenia are anticipated to change in the coming years. The rising trend in the adoption of long-acting injectable (LAI) antipsychotic medications is a primary catalyst for the expansion of the global market for schizophrenia drugs. The World Health Organization’s Comprehensive Mental Health Action Plan for the period 2013-2030 is set to contribute significantly to promoting mental health awareness and facilitating access to high-quality and affordable care for mental health disorders, aiming to reach an additional 100 million people.
Furthermore, the schizophrenia pipeline is very robust; many potential therapies are being investigated for the treatment of schizophrenia, and it is safe to predict that the treatment space will significantly impact the schizophrenia market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the schizophrenia market in the 7MM.
However, several factors are impeding the growth of the schizophrenia market. The current therapeutic options are burdened by adverse effects such as weight gain, sedation, and abnormal movement disorders. This leads to a staggering 74% of patients discontinuing their medications within 18 months. The schizophrenia market expansion could be hindered by factors like the growing availability of generic alternatives and the imminent patent expirations of approved therapies, which might result in a decrease in the schizophrenia market revenue.
Moreover, schizophrenia treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the schizophrenia market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the schizophrenia market growth.
| Schizophrenia Report Metrics | Details |
| Study Period | 2019–2032 |
| Schizophrenia Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Schizophrenia Market Size in 2021 | USD 8.6 Billion |
| Key Schizophrenia Companies | Otsuka Pharmaceutical Development & Commercialization, Inc., H. Lundbeck A/S, Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Merck, SyneuRx International (Taiwan) Corp, Reviva Pharmaceuticals, Sunivion, PsychoGenics, Neurocrine Biosciences, Takeda, Minerva Neurosciences, BioXcel Therapeutics Inc, Teva Branded Pharmaceutical Products R&D, Inc., Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others |
| Key Schizophrenia Therapies | Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others |
Scope of the Schizophrenia Market Report
- Therapeutic Assessment: Schizophrenia current marketed and emerging therapies
- Schizophrenia Market Dynamics: Attribute Analysis of Emerging Schizophrenia Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Schizophrenia Market Access and Reimbursement
Discover more about schizophrenia drugs in development @ Schizophrenia Clinical Trials
Table of Contents
| 1. | Schizophrenia Market Key Insights |
| 2. | Schizophrenia Market Report Introduction |
| 3. | Schizophrenia Market Overview at a Glance |
| 4. | Schizophrenia Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Schizophrenia Treatment and Management |
| 7. | Schizophrenia Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Schizophrenia Marketed Drugs |
| 10. | Schizophrenia Emerging Drugs |
| 11. | Seven Major Schizophrenia Market Analysis |
| 12. | Schizophrenia Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Schizophrenia Epidemiology Forecast
Schizophrenia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted schizophrenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Schizophrenia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key schizophrenia companies, including Otsuka Pharmaceutical Development & Commercialization, Inc., Gedeon Richter Ltd., Lyndra Therapeutics, Neurocrine Bioscience, Takeda Pharmaceutical Company, Memory Pharmaceuticals, Hoffmann-La Roche, Neurocrine Biosciences, Boehringer Ingelheim, Meiji Seika Pharma Co., Ltd., SK Life Science, Inc., Alkermes, Inc. , Solvay Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, SyneuRx International (Taiwan) Corp, BioXcel Therapeutics Inc, Cognitive Research Corporation, Amarex Clinical Research, Forum Pharmaceuticals Inc, Amneal Pharmaceuticals, LLC, Recognify Life Sciences, Accutest Research Laboratories (I) Pvt. Ltd., Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Janssen, LP, Delpor, Inc., Jiangsu Hansoh Pharmaceutical, Cerevel Therapeutics, LLC, Zogenix, Inc., Luye Pharma, Reviva Pharmaceuticals, Alkermes, Inc., Karuna Therapeutics, Autifony Therapeutics, Neumora Therapeutics, Adex Therapeutics, among others.
Dementia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia companies, including Hoffmann-La Roche, Forest Laboratories, Inc., Janssen Pharmaceuticals, Inc., Merck and Co., Inc., Novartis, among others.
Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease companies, including Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicine, Intra-Cellular Therapies, Hoffmann-La Roche, Prothena Corp, among others.
Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer’s disease companies including Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., among others.
Psychosis in Parkinson’s and Alzheimer’s Disease Market
Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson’s and Alzheimer’s disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
